Thromb Haemost 2011; 106(02): 230-239
DOI: 10.1160/TH11-02-0077
Theme Issue Article
Schattauer GmbH

Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events

Matthias K. Freynhofer
1  3rd Medical Department, Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna, Austria
2  Ludwig Boltzmann Cluster for Cardiovascular Research, Vienna, Austria
,
Ivan Brozovic
1  3rd Medical Department, Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna, Austria
,
Veronika Bruno
1  3rd Medical Department, Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna, Austria
3  Department of Obstetrics and Gynecology, Wilhelminenhospital, Vienna, Austria
,
Serdar Farhan
1  3rd Medical Department, Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna, Austria
,
Birgit Vogel
1  3rd Medical Department, Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna, Austria
,
Gabriele Jakl
1  3rd Medical Department, Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna, Austria
,
Martin Willheim
4  Department of Laboratory Medicine, Wilhelminenhospital, Vienna, Austria
,
Wolfgang Hübl
4  Department of Laboratory Medicine, Wilhelminenhospital, Vienna, Austria
,
Johann Wojta
2  Ludwig Boltzmann Cluster for Cardiovascular Research, Vienna, Austria
5  Department of Cardiology, Medical University of Vienna, Vienna, Austria
,
Kurt Huber
1  3rd Medical Department, Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna, Austria
2  Ludwig Boltzmann Cluster for Cardiovascular Research, Vienna, Austria
› Author Affiliations
Further Information

Publication History

Received: 07 February 2011

Accepted after major revision: 08 April 2011

Publication Date:
25 November 2017 (online)

Summary

Reduced antiplatelet effect of clopidogrel assessed with multiple electrode aggregometry (MEA) and vasodilator stimulated phosphoprotein-phosphorylation (VASP-P) assay has been proven to predict major adverse cardiovascular events (MACE) after coronary stenting. So far no consecutive registry has evaluated the usefulness of different adenosine diphosphate-based platelet function tests to predict outcome in unselected patients. Hence, our objective was to determine the feasibility of MEA and VASP-P for clinical routine and whether low-response to clopidogrel as determined by MEA and/or the VASP-P assays predicts MACE in a “real-life” population undergoing coronary stenting. Threehundred consecutive patients were included in this prospective registry. Blood was sampled 6–24 hours after stenting to measure MEA and VASP-P. The use of glycoprotein-IIb/IIIa-blockers limited MEA to 196 measurements. Concerning the VASP-P assay, 300 measurements were achieved. Receiver Operating Characteristics (ROC)-curves of sensitivity and specificity estimates for MACE were plotted for VASP-P assay. The area under the ROC-curve was 0.683 (p=0.014) for the platelet reactivity index (PRI) calculated from median fluorescence intensities (FI) with an optimal cut-off at 60.2% PRI. Patients above 60.2% had a significantly increased risk for MACE at six months follow-up (p=0.007). Estimating the cut-offs for the PRI from mean FI (52%) or from geometric mean FI (56.6%) led to clinically relevant differences. VASP-P assay is feasible for clinical routine to measure clopidogrel effects and to predict post-procedural MACE in unselected patients. With regard to differing cut-offs, exact standardisation of the VASP-P assay is mandatory. The use of GP-IIb/IIIa-blockers prevents MEA testing and limits its usability in unselected patients.